Global Radiotherapy Market And Forecast To 2030

(MENAFN- Market Press Release) September 9, 2025 5:07 am - Apelo Consulting has released a report on Global Radiotherapy Market (By Type, Procedure, Application, End User, Country Analysis), Company Profiles, Market Dynamics and Recent Developments – Forecast to 2030

The global radiotherapy market was valued at USD 7,100 Million in 2023, and is projected to reach USD 10,270 Million by 2030. Radiotherapy, also known as radiation therapy, is a medical treatment used to manage cancer and certain non-cancerous conditions. This non-invasive approach can be delivered externally through external beam radiotherapy or internally by placing radioactive materials close to or within the tumor, a method called brachytherapy. The primary goal of radiotherapy is to eradicate cancer cells while minimizing damage to surrounding tissues. According to Radiation Oncology Targeting Cancer, radiotherapy is responsible for 40% of all cures for cancer globally, as well as enhancing life quality for many more.

The radiotherapy industry is currently experiencing a transformation driven by technological advancements. Innovative tools and techniques-such as precision treatment delivery methods like intensity-modulated radiation therapy (IMRT), image-guided radiotherapy (IGRT), and stereotactic body radiation therapy (SBRT), which deliver highly targeted radiation doses to cancer cells-are significantly enhancing treatment outcomes. Additionally, the introduction of MRI LINAC systems allows for real-time imaging during therapy, and the integration of artificial intelligence in treatment planning and data analysis is further refining the accuracy and efficiency of radiotherapy. These technological advancements aim to enhance the performance of radiotherapy delivery systems and broaden their range of applications.

The expansion of the radiotherapy market is fueled by multiple factors, including the increasing prevalence of cancer, continuous technological innovations, greater awareness of the advantages of radiotherapy, rising healthcare spending, and the growing implementation of particle therapy in cancer treatment. According to GLOBOCAN 2022, approximately 19.98 million new cancer cases were reported in 2022. This number is projected to grow to 24.11 million by 2030 and reach 30.97 million by 2045. Radiotherapy continues to play a vital role in cancer care, with more than half of all cancer patients undergoing this treatment during their illness.

Key Highlights of the Report

. The external beam radiotherapy (EBRT) segment dominated the global radiotherapy market in 2024. External beam radiotherapy is a widely and well-established cancer treatment modality which has the high ability to kill tumor in the early phases as compared to conventional therapies with less side effects. The high effectiveness of EBRT across various cancer, non-invasive nature of treatment and continuous technological advancements in external beam radiotherapy such as MR-Linac, particle therapy, stereotactic radiosurgery and IMRT to deliver radiation externally with high accuracy and precision makes this mode suitable for many types of cancer treatment.

. Based on segment, the compact advanced radiotherapy systems dominated the global external beam radiotherapy (EBRT) market in 2024. The demand for compact advanced radiotherapy systems such as CyberKnife, Gamma Knife, and TomoTherapy have witnessed significant growth in recent years.

. Particle therapy is a non-invasive treatment option that delivers high doses of radiation to cancer cells while minimizing damage to surrounding healthy tissues. This makes it a striking option for patients that want to avoid the side effects associated with traditional cancer treatments such as chemotherapy and surgery. The development of compact and less expensive proton therapy systems has contributed to the expansion of particle therapy facilities globally.
. The internal beam radiotherapy also known as brachytherapy allows for precise and targeted radiation delivery while minimizing radiation exposure to surrounding healthy tissues. Brachytherapy is increasingly being used in various cancer types, including prostate, cervical, and breast cancer. The growing awareness of its benefits, advancements in imaging and treatment planning, and improved techniques have contributed to the rapid growth of internal beam radiotherapy.

. Systemic radiotherapy is an effective treatment for cancers of the bone, prostate, and thyroid, among others. It is predicted that the systemic radiotherapy segment will capture over 15% share of the total radiotherapy market by 2030.

. Based on procedure, the external beam radiotherapy (EBRT) segment dominated the overall market in 2024, due to increased adoption in treatment of various types of cancers. The rapid technological advancements and investigation of such technologies on various cancer treatment are increasing demand for LINACs and MR-LINACs, thereby, contributing to the growth of radiotherapy market.

. Based on application, the breast cancer dominated the global radiotherapy market in 2024. Radiotherapy techniques, notably three-dimensional conformal radiotherapy (3D-CRT) and intensity-modulated radiation therapy (IMRT), have advanced significantly. These advancements have not only bolstered treatment precision but have also enhanced its effectiveness, thereby reducing side effects and improving patient outcomes.

. The prostate cancer application is another growing segment of the radiotherapy market, owing to the rising incidence of prostate cancer coupled with the high success rate compared to other cancer types. Radiotherapy is a highly effective treatment for prostate cancer, with success rates ranging from 80%-90%.

. Based on end user, the hospitals segment dominated the global radiotherapy market in 2024. This is because radiotherapy is a long-term procedure that involves frequent hospital visits and often inpatient treatment. The availability of advanced medical technologies and skilled radiation oncologists is what prompts cancer patients to choose hospitals for their radiotherapy procedures.

. North America dominated the global radiotherapy market in 2024, owing to a high number of cancer patients in the region undergoing radiotherapy procedures, presence of well-established healthcare facilities, favorable reimbursement policies, and strong foothold of market players in the region.

. The Asia Pacific region is projected to be the fastest-growing segment of the global radiotherapy market. This growth is driven by several factors, including increased investment in healthcare infrastructure, a growing number of patients, and heightened awareness of the advantages of radiotherapy. Notably, countries such as China and India are experiencing significant market expansion, fueled by their large populations and ongoing initiatives to enhance cancer care services.

MENAFN11092025003520003262ID1110047113